| Case . | Age (y)/sex . | Cytogenetics, dysplasia, relapse information . | FAB . | Prognostic category . | % change in endothelial proliferation . |
|---|---|---|---|---|---|
| 1 | 55/F | De novo, Inv(16), + 22 | M4 | F/I | − 12 |
| 2 | 50/M | De novo, 46XY | M5a | F/I | − 27 |
| 3 | 55/F | De novo, 46XX | M1 | F/I | − 20 |
| 4 | 40/M | De novo, t(15;17), add 7(q36) | M3 | F/I | − 32 |
| 5 | 19/M | Inv 16 | M4Eo | F/I | − 42 |
| 6 | 32/M | De novo, + 11 | M1 | F/I | − 13 |
| 7 | 76/M | De novo, + 8 | M0 | F/I | − 50 |
| 8 | 67/M | t(15;17) | M3 | F/I | − 41 |
| 9 | 68/F | De novo, + 4, + 11 | M4 | F/I | − 21 |
| 10 | 18/F | Relapsed, t(6;9) | M1 | U | − 15 |
| 11 | 66/M | De novo, 46XY, relapse within 2 months | M2 | U | + 53 |
| 12 | 64/M | + 8, dyspoiesis | M1 | U | + 5.5 |
| 13 | 68/M | History of MDS, 46XY | M2 | U | − 31 |
| 14* | 31/F | t(11;19), relapsed within 6 months, dyspoiesis | M4 | U | + 35 |
| 15 | 54/M | 11q23 | M5a | U | − 19 |
| 16 | 83/F | Multiple relapses | M5a | U | + 5 |
| 17 | 68/F | t(9;22) and − 7 | Mixed lineage | U | + 3 |
| 18* | 42/M | Complex karyotype | M1 | U | + 0 |
| 19* | 55/M | History of MDS | M5 | U | − 27 |
| 20 | 61/F | History of CMML, complex karyotype | M4 | U | − 12 |
| 21 | 53/F | History of MDS, complex karyotype | M2 | U | − 26 |
| Case . | Age (y)/sex . | Cytogenetics, dysplasia, relapse information . | FAB . | Prognostic category . | % change in endothelial proliferation . |
|---|---|---|---|---|---|
| 1 | 55/F | De novo, Inv(16), + 22 | M4 | F/I | − 12 |
| 2 | 50/M | De novo, 46XY | M5a | F/I | − 27 |
| 3 | 55/F | De novo, 46XX | M1 | F/I | − 20 |
| 4 | 40/M | De novo, t(15;17), add 7(q36) | M3 | F/I | − 32 |
| 5 | 19/M | Inv 16 | M4Eo | F/I | − 42 |
| 6 | 32/M | De novo, + 11 | M1 | F/I | − 13 |
| 7 | 76/M | De novo, + 8 | M0 | F/I | − 50 |
| 8 | 67/M | t(15;17) | M3 | F/I | − 41 |
| 9 | 68/F | De novo, + 4, + 11 | M4 | F/I | − 21 |
| 10 | 18/F | Relapsed, t(6;9) | M1 | U | − 15 |
| 11 | 66/M | De novo, 46XY, relapse within 2 months | M2 | U | + 53 |
| 12 | 64/M | + 8, dyspoiesis | M1 | U | + 5.5 |
| 13 | 68/M | History of MDS, 46XY | M2 | U | − 31 |
| 14* | 31/F | t(11;19), relapsed within 6 months, dyspoiesis | M4 | U | + 35 |
| 15 | 54/M | 11q23 | M5a | U | − 19 |
| 16 | 83/F | Multiple relapses | M5a | U | + 5 |
| 17 | 68/F | t(9;22) and − 7 | Mixed lineage | U | + 3 |
| 18* | 42/M | Complex karyotype | M1 | U | + 0 |
| 19* | 55/M | History of MDS | M5 | U | − 27 |
| 20 | 61/F | History of CMML, complex karyotype | M4 | U | − 12 |
| 21 | 53/F | History of MDS, complex karyotype | M2 | U | − 26 |
Sample analyzed was from time of relapse (after treatment).
FAB indicates French-American-British classification.